Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Article Abstract:

The analysis of pooled safety data from the pivotal phase three T-20 Versus Optimized Background Regimen Only (TORO) trials indicates that enfuvirtide is a well-tolerated antiretroviral agent with a maintained safety profile over 48 weeks in treatment-experienced HIV-1-infected adults. It is found that the rates of other adverse agents favored enfuvirtide or were generally comparable between treatments.

Care and treatment, Drug therapy, Combination, Combination drug therapy

---

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials

Article Abstract:

Exploratory analyses to compare treatment effects between the enfuvirtide and control groups by different factors after 48 weeks that were carried out are discussed. It was demonstrated that the efficacy to enfuvirtide is durable plus optimized background over 48 weeks.

Government regulation, Drug therapy, Licensing, certification and accreditation

---

Similar abstracts:

• Abstracts: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.